NW-301V(NW-301V) - 药物靶点：KRAS G12V_在研适应症：晚期恶性实体瘤_专利_临床

概要

基本信息

药物类型

TCR-T细胞疗法

别名

TCR-T T cell targeting KRAS G12V mutation

靶点

KRAS G12V

作用方式

调节剂

作用机制

KRAS G12V modulators(GTPase KRas G12V modulators)

治疗领域

肿瘤

在研适应症

晚期恶性实体瘤

非在研适应症-

原研机构

新景智源生物科技（苏州）有限公司

在研机构

新景智源生物科技（苏州）有限公司

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

3

项与 NW-301V 相关的临床试验

NCT06484556

/ Recruiting临床1期IIT

Open-label, Single-arm, Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Autologous TCR-T Cell Therapy in Subjects With Advanced Solid Tumors

An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor

开始日期2024-06-19

申办/合作机构

华中科技大学同济医学院附属协和医院

[+1]

NCT06484790

/ Recruiting临床1期IIT

Open-label, Single-arm, Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Autologous TCR-T Cell Therapy in Subjects With Advanced Solid Tumors

An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor

开始日期2024-04-08

申办/合作机构

天津市肿瘤研究所

[+1]

NCT06478251

/ Recruiting临床1期IIT

Open-label, Single-arm, Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Autologous TCR-T Cell Therapy in Subjects With Advanced Solid Tumors

An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor.

开始日期2024-03-31

申办/合作机构